Search results
3 dni temu · Stephan Jackman, CEO of Alzamend, stated, “We are very pleased to announce that Alzamend has regained compliance with Nasdaq’s listing standards. We presented a strategic plan of compliance to the Panel at our hearing in May, which we have successfully executed upon. Regaining compliance with Nasdaq listing standards was an important goal ...
- Alzamend Neuro Announces Full Data Set from Phase IIA ... - BioSpace
Such lithium dose mitigation could redefine the landscape of...
- Alzamend Neuro Announces Full Data Set from Phase IIA ... - BioSpace
4 dni temu · ATLANTA - Alzamend Neuro, Inc. (NASDAQ:ALZN), firma biofarmaceutyczna w fazie klinicznej, ogłosiła, że ponownie spełnia wymogi Nasdaq dotyczące kapitału własnego akcjonariuszy. Spółka, która pracuje nad terapiami na chorobę Alzheimera i inne zaburzenia psychiczne, otrzymała 14.10.2024 r. oficjalne powiadomienie od Nasdaq Stock ...
3 dni temu · Alzamend had not regained compliance by March 25, 2024, and Nasdaq determined to delist Alzamend’s common stock. Alzamend appealed the delisting determination to a Hearings Panel (the " Panel...
2 dni temu · Such lithium dose mitigation could redefine the landscape of neuropsychiatric, neurodegenerative, and neurological treatment practices. About Alzamend Neuro. Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BPD, MDD and PTSD.
2 dni temu · ATLANTA–Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received the final full data set from its ...
4 dni temu · Alzamend Neuro Regains Compliance with Nasdaq Listing Standards. ATLANTA, GA, October 15, 2024 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today ...
3 sty 2017 · The gross proceeds from the offering to Alzamend, before deducting underwriting discounts and commissions and other offering expenses payable by Alzamend, are expected to be $12.5 million. In addition, the underwriters have been granted a 45-day option to purchase up to an additional 375,000 shares of common stock, at the initial public ...
